Edmund CP Chedgy

Post-doctoral Uro-Oncology Research Fellow

Vancouver Prostate Centre and University of British Columbia, Canada.

JOURNAL REVIEWED: PROSTATE CANCER AND PROSTATIC DISEASES – September 2012 – April 2015

Latest Contribution

The EP2 receptor – a novel target for prostate cancer?

1 July 2014 | | URO - Basic Science Research, URO - Urologic Oncology

This basic science paper sets out to evaluate the effects that celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, have on prostate cancer cell lines and evaluated the mechanisms behind these effects. COX-2 induces the production of prostaglandins, which promote cell proliferation...

  • 1
  • 2 (current)